Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary06/21/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/21/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has
Toggle Summary06/20/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/20/16 -- Medgenics, Inc. (NYSE: MDGN), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement.
Toggle Summary06/17/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/17/16 -- Medgenics, Inc. (NYSE: MDGN) today announced the enrollment of the first patient into the SAGA ( S tudy of A dolescent G lutamate Receptor Network Copy Number Variant A DHD) trial -- a Phase 2/3 clinical trial to evaluate adolescent patients with
Toggle Summary06/15/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/15/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the JMP Life Sciences Conference at 12:30 PM Eastern Time on Tuesday, June 21, 2016 in New York, NY . About Medgenics, Inc.
Toggle Summary06/06/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/06/16 -- (NYSE MKT: MDGN) Collaboration with Kyowa Hakko Kirin to develop anti-LIGHT monoclonal antibody Second program from research collaboration with The Children's Hospital of Philadelphia (CHOP) Center for Applied Genomics (CAG) Data from signal finding
Toggle Summary06/01/2016
PHILADELPHIA, PA -- (Marketwired) -- 06/01/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016 at 3:30 p.m.
Toggle Summary05/20/2016
PHILADELPHIA, PA -- (Marketwired) -- 05/20/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the annual UBS Global Healthcare Conference in New York, NY on Wednesday May 25, 2016 at 8:00 a.m.
Toggle Summary05/10/2016
PHILADELPHIA, PA -- (Marketwired) -- 05/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) Rapid enrollment in phenotype/genotype study of mGluR positive ADHD patients Data support the prevalence of mGluR mutation in broad ADHD population Enrollment to begin in Phase 2/3 clinical trial in mGluR+ ADHD
Toggle Summary05/03/2016
PHILADELPHIA, PA -- (Marketwired) -- 05/03/16 -- Medgenics, Inc. (NYSE MKT: MDGN) today announced the appointment of Michael Diem , MD as Senior Vice President of Corporate and Business Development. Dr. Diem will be a key member of the Medgenics leadership team, heading all business and corporate
Toggle Summary05/02/2016
PHILADELPHIA, PA -- (Marketwired) -- 05/02/16 -- Medgenics, Inc. (NYSE MKT: MDGN) will host a conference call and live audio webcast on Tuesday, May 10, 2016 at 8:30 a.m. EDT to discuss the financial results for the first quarter ended March 31, 2016 .